hypoxia-inducible factor-1α

Overview

Hypoxia-inducible factor-1α (HIF-1α) is the oxygen-sensitive regulatory subunit of the heterodimeric transcription factor HIF-1, which serves as the master regulator of cellular and systemic responses to hypoxia in mammalian tissues. Under normoxic conditions, HIF-1α is continuously synthesized but rapidly targeted for proteasomal degradation through hydroxylation by prolyl hydroxylases — including EGLN2 (PHD1) — which marks the protein for recognition by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex. When oxygen tension falls, prolyl hydroxylase activity is suppressed, HIF-1α accumulates, translocates to the nucleus, and dimerizes with the constitutively expressed HIF-1β subunit to activate transcription of hundreds of target genes bearing hypoxia-response elements (HREs). Key transcriptional targets include VEGFA, which drives angiogenesis; glycolytic enzymes such as hexokinase (HK2); and cytokines including interleukin-6. Through these programs, HIF-1α coordinates oxygen delivery, metabolic reprogramming, and immune modulation in both physiological and pathological settings.

The biological significance of HIF-1α spans a wide spectrum of disease contexts. In oncology, HIF-1α is constitutively stabilized in solid tumors by the hypoxic, lactate-rich tumor microenvironment, where it promotes glycolysis via the HIF-1α/HK2 axis, suppresses anti-tumor immunity through upregulation of PD-L1 and expansion of regulatory T cells, and enhances metastatic potential through targets such as MMP-9. Beyond cancer, HIF-1α plays critical roles in cardiovascular disease, ischemia-reperfusion injury, wound healing, hematopoiesis, and tissue repair. Its broad involvement in disease pathophysiology has made it both a therapeutic target — where inhibition is sought in cancer — and a potential therapeutic effector, where its activation is harnessed to promote tissue vascularization and regeneration.

Focus of Latest Publications

Recent publications have examined hypoxia-inducible factor-1α (HIF-1α) in a range of hypoxia-related disease settings, with particular attention to its role as a therapeutic target or pathway component. In cancer research, HIF-1α was studied in relation to hypoxic tumor adaptation, metastasis, immune evasion, and treatment resistance. One study reported that endogenous HIF-1α overexpression in CAR-T cells improved tumoricidal activity and infiltration under hypoxic conditions, with metabolic effects linked to increased glycolysis and preserved mitochondrial integrity. Another investigation found that a compound targeting RSK2 suppressed triple-negative breast cancer migration and invasion by downregulating the HIF-1α/MMP-9 pathway. Additional work showed that quercetin-containing nanoparticles reduced HIF-1α expression to alleviate hypoxia-driven glycolytic support of ferroptosis resistance in triple-negative breast cancer, while a separate study identified dual HIF-1/2 inhibitors that directly bind conserved domains of HIF-1α and HIF-2α and inhibit tumor growth, vascularization, and resistance to immune checkpoint therapy.

Several studies focused on HIF-1α in regenerative and inflammatory contexts. In immune thrombocytopenia, HIF-1α was reported to mediate SPHK2 and sphingosine 1-phosphate production, and reduced HIF-1α expression in megakaryocytes was associated with impaired proplatelet formation; all-trans retinoic acid upregulated HIF-1α and corrected this defect in vitro and in vivo. In diabetic pressure ulcer healing, CD73-positive mesenchymal stem cells improved wound repair and endothelial function through a HIF-1α-dependent increase in VEGFA under hypoxic conditions. In critical limb ischemia, extracellular vesicles loaded with a stabilized, constitutively active HIF-1α improved perfusion and reduced necrosis, promoted vascular remodeling, and increased CD163+ perivascular macrophages through endothelial Dll1-dependent macrophage differentiation.

HIF-1α was also investigated in neuroinflammatory and ischemic injury models. One study described hyperbaric oxygen preconditioning as disrupting an LRG1-HIF-1α-IL-6-STAT3 amplification loop to attenuate pyroptosis and ischemia-reperfusion injury. In dogs with thoracolumbar intervertebral disc disease receiving acupuncture, plasma HIF-1α was measured alongside inflammatory biomarkers, but no significant treatment-related change in HIF-1α was observed, and the biomarker was considered exploratory in that clinical setting. Another study in thoracic aortic dissection examined Xuefu Zhuyu decoction in relation to vascular smooth muscle cell phenotypic switching and oxidative stress via the JAK2/STAT3/HIF-1α pathway.

Overall, these publications portray HIF-1α as a central hypoxia-responsive regulator linked to metabolic reprogramming, angiogenesis, immune-cell behavior, and tissue remodeling. Across the studies, HIF-1α was modulated by diverse interventions including small activating RNA, all-trans retinoic acid, extracellular vesicles, mesenchymal stem cells, quercetin-based nanoparticles, hyperbaric oxygen preconditioning, acupuncture, and herbal decoction, with reported effects ranging from enhanced antitumor activity and vascular repair to improved megakaryopoiesis and altered inflammatory signaling.

Key Publications

• NEWJun Clinical investigation of plasma HIF-1α and inflammatory biomarkers in dogs with thoracolumbar intervertebral disc disease receiving acupuncture treatment. (Veterinary research communications, 2026, PMID 42371222): "...including hypoxia-inducible factor-1α (HIF-1α), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and total plasma NAD(H) levels, in dogs with thoracolumbar intervertebral disc disease (TL-IVDD) undergoing acupuncture treatment."
• May Overexpression of HIF-1α via small activating RNA enhances CAR-T cell function in hypoxic microenvironments. (Pharmacological research, 2026, PMID 42105819): "Driven by clinical transcriptomic and protein evidence implicating hypoxia-inducible factor-1α (HIF-1α) in metabolic reprogramming, we developed a non-viral CAR-T cell preparation platform using a piggyBac transposon system to co-deliver a CAR construct and a small activating RNA (saRNA) to drive endogenous HIF-1α overexpression (HIF1AOE)."
• May ATRA improves megakaryopoiesis in immune thrombocytopenia through up-regulating the HIF-1α/SPHK2/S1P pathway. (Science advances, 2026, PMID 42090514): "Furthermore, hypoxia-inducible factor-1α (HIF-1α) was shown to mediate SPHK2 and S1P production."
• May HBO-PC Reprograms Neuroimmune Metabolism Through Disruption of the LRG1-HIF-1α-IL-6-STAT3 Amplification Loop Attenuates Pyroptosis and Ischemia-Reperfusion Injury. (CNS neuroscience & therapeutics, 2026, PMID 42053428): "Hyperbaric oxygen preconditioning (HBO-PC) exhibits neuroprotective effects, but its mechanisms remain unclear."
• May Vitexicarpin Directly Targets RSK2 to Attenuate Migration and Invasion of Triple-Negative Breast Cancer Through Modulating HIF-1α/MMP-9 Pathway. (Drug development research, 2026, PMID 42041151): "Mechanistically, we found that HIF-1α/MMP-9 was involved in VIT-mediated inhibition of migration and invasion of TNBC."
• May Self-assembled nanoparticles overcoming hypoxic and acidic microenvironment to synergistically potentiate ferroptosis in triple-negative breast cancer. (International journal of pharmaceutics, 2026, PMID 41946426): "Simultaneously, QUE mitigates the hypoxic tumor microenvironment by suppressing the expression of hypoxia-inducible factor 1-alpha (HIF-1α) and hexokinase β (HK-β), thereby inhibiting glycolysis, reducing LA production, and impeding GSH synthesis."
• May Targeting conserved domains of hypoxia-inducible factors for cancer therapy. (The Journal of experimental medicine, 2026, PMID 41941275): "...which bind directly to highly conserved domains of HIF-1α and HIF-2α, disrupt dimerization with HIF-1β, and trigger proteasomal degradation, thereby inhibiting HIF-1/2 transcriptional activity."
• May Hypoxia‑induced exosomal CAMTA1 promotes radio‑resistance in MDA‑MB‑231 cells by regulating NRG1 to mediate M2 macrophage polarization. (International journal of oncology, 2026, PMID 41891984): "Reverse transcription-quantitative (RT-q) PCR and immunoblotting analysis were used to detect the expressions of neuregulin 1 (NRG1), CAMTA1 and hypoxia-inducible factor-1α."
• Jun Extracellular vesicle-mediated HIF-1α delivery promotes durable vascular remodeling via endothelial Dll1-dependent CD163+ macrophage differentiation. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41887468): "we engineered a pH-responsive intein-based platform to load extracellular vesicles (EVs) with a stabilized, constitutively active form of hypoxia-inducible factor-1α (HIF-1α)."
• May CD73+ mesenchymal stem cell (MSC) transplantation improves pressure ulcer healing by promoting angiogenesis through the HIF-1α/VEGF pathway in diabetic mice. (Experimental cell research, 2026, PMID 41819469): "CD73 could modulate vascular endothelial growth factor A (VEGFA) expression under hypoxic conditions via a hypoxia-inducible factor-1α (HIF-1α)-dependent pathway."